Third Harmonic Bio (THRD) | Stock Overview & Key Data
Third Harmonic Bio Performance Comparison
Stock Range
Today's Range
Low: $5.38
High: $5.38
on August 13, 2025
52 Week Range
Low: $3.18
High: $16.02
on February 11, 2025
on September 20, 2024
All-Time High: $24.59 on October 31, 2022
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$242.8M
EPS
-1.24
P/E Ratio (TTM)
12.46
Forward P/E
-3.49
P/B Ratio
0.89
PEG Ratio
0.17
Div. Yield
N/A
ROE
-19.94%
Beta
2.132
Debt to Equity
1.10
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
0.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-14.60%
Return on Equity (TTM)
-19.94%
EBITDA
$-64.2M
Net Income (TTM)
$-53.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Third Harmonic Bio THRD | 242.79M Micro-cap | 0.00% | -1.28% | 4.47% | 56.85% | -51.27% | -53.82% | -70.11% | -70.11% |
| Vertex VRTX | 124.11B Large-cap | -1.04% | -16.52% | -12.54% | -18.50% | -3.63% | -21.15% | 39.13% | 46.72% |
| Regeneron REGN | 61.25B Large-cap | -1.49% | 4.04% | -4.08% | -16.89% | -18.80% | -50.98% | 0.01% | 0.06% |
| Editas Medicine EDIT | 146.11M Micro-cap | -8.21% | -0.77% | 40.44% | 33.85% | 96.18% | -31.28% | -82.67% | -91.57% |
| Silence Therapeutics SLN | 203.97M Micro-cap | -10.09% | -22.42% | -19.02% | 6.89% | -33.10% | -74.80% | -54.58% | -75.33% |
| Alector ALEC | 139.71M Micro-cap | -6.75% | 45.96% | 65.49% | 43.29% | 24.34% | -55.49% | -77.53% | -81.06% |
Ownership & Short Interest
Insider Ownership
9.11%
Institutional Ownership
80.12%
Shares Short
1M
Short Ratio
6.95
Short % of Shares Outstanding
5.17%
Average 10-Day Volume
174K
Average 90-Day Volume
175K
Warning: Undefined variable $nickname in /usr/local/lsws/wordpress/wp-content/themes/egnitech-devyara/templates/stock-overview.php on line 328
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is THRD's 52-week high and low?
- In the last 52 weeks, Third Harmonic Bio reached a high of $16.02 (on September 20, 2024) and a low of $3.18 (on February 11, 2025).
- What is the market cap and P/E ratio for THRD?
- Curious about Third Harmonic Bio's size and valuation? Its market capitalization stands at 242.79M. When it comes to valuation, the P/E ratio (trailing twelve months) is 12.46, and the forward P/E (looking ahead) is -3.49.
- Does THRD pay dividends? If so, what's the yield?
- As for dividends, Third Harmonic Bio isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Third Harmonic Bio's main competitors or similar companies to consider before investing?
When looking at Third Harmonic Bio, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX124.11B Healthcare Biotechnology -21.15% 39.13% Regeneron
REGN61.25B Healthcare Biotechnology -50.98% 0.01% Editas Medicine
EDIT146.11M Healthcare Biotechnology -31.28% -82.67% Silence Therapeutics
SLN203.97M Healthcare Biotechnology -74.80% -54.58% Alector
ALEC139.71M Healthcare Biotechnology -55.49% -77.53% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Third Harmonic Bio, Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Third Harmonic Bio's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -19.94%, the Debt to Equity ratio from the most recent quarter is 1.10, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for THRD?
- Looking at Third Harmonic Bio's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of THRD stock is held by insiders and institutions?
- Wondering who owns Third Harmonic Bio stock? Company insiders (like executives and directors) hold about 9.11% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 80.12%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.